Report : North America Small Intestinal Bacterial Overgrowth (SIBO) Diagnostics Market Forecast to 2028 - COVID-19 Impact and Regional Analysis By Diagnosis (Breath Testing, Small Intestine Aspirate and Fluid Culture Test, Blood Test, and Others) and Type (Hydrogen-predominant SIBO, Methane-predominant SIBO, and Recurrent SIBO)
Breath Testing Segment to Dominate North America Small Intestinal Bacterial Overgrowth (SIBO) Diagnostics Market during 2021–2028
According to a new market research study on “North America Small Intestinal Bacterial Overgrowth (SIBO) Diagnostics Market to 2028 – COVID-19 Impact and Regional Analysis and Forecast by Diagnosis and Type” is expected to reach US$ 73,794.03 thousand by 2028 from US$ 53,452.06 thousand in 2021. The market is estimated to grow at a CAGR of 4.7% from 2021 to 2028. The report provides trends prevailing in the North America small intestinal bacterial overgrowth (SIBO) diagnostics market along with the drivers and restraints pertaining to the market growth. Growing prevalence of IBS and SIBO and increasing advantages of breath test are the major factor driving the growth of the North America small intestinal bacterial overgrowth (SIBO) diagnostics market. However, limitations of diagnosis hinders the growth of North America small intestinal bacterial overgrowth (SIBO) diagnostics market.
In case of COVID-19, North America is highly affected specially the US. Industrial sectors in the countries such as the US and Canada has experienced disruption in various industries, including healthcare. However, the need for diagnosis and treatment for the COVID positive patients has carried on business cycles in the medical sector. In addition, the rising demand for personal protective equipment has tried to stabilize the business cycle for the healthcare industry. According to an article issued by Harvard Medical School, infectious viral particles can live in the air for three hours. As a result, it can cause patient scheduling obstructions and put others at risk for contracting the virus. For healthcare providers demanding to test for GI-related problems offered by patients, a substitute for in-office breath testing must be granted due to the potential spread of COVID-19 through aerosolization. Unfortunately, the possible aerosolization spread of COVID-19 makes breath testing in-office comparatively unsafe and has been in a bit of a dilemma in the clinic during this pandemic. The small intestinal bacterial overgrowth diagnostics market also witnessed major decline due to lowered number of diagnostic procedures. Substantial focus on management of COVID had direct impact on diagnostics of abdominal conditions such as irritable bowel syndrome, SIBO, and lactose intolerance. In addition, patients showed reluctance for breath and blood tests due to fear of COVID infection. These factors consequently led to adverse impact on North America small intestinal bacterial overgrowth market during the pandemic period. However, the market is expected to witness considerable growth post-pandemic. Certain factors such as rise in prevalence of SIBO and IBS are estimated to show positive impact on market growth.
The North America small intestinal bacterial overgrowth (SIBO) diagnostics market has been segmented based on diagnosis, type, and country. Based on diagnosis, the market has been segmented into breath testing, small intestine aspirate and fluid culture test, blood test, and others. The breath testing segment dominated the market in 2020 and also expected to be fastest growing during forecast period. The breath testing has been further segmented into 14c xylose breath test, hydrogen breath test, 14c glycocholic acid breath test, and malabsorption tests. Based on type, the market has been segmented into hydrogen-predominant SIBO, methane-predominant SIBO, and recurrent SIBO. The hydrogen-predominant SIBO segment dominated the market in 2020 and also expected to be fastest growing during forecast period. Based on country, the market has been segmented into the US, Canada, and Mexico.
Aerodiagnostics, LLC.; Commonwealth Diagnostics International; DirectLabs, LLC.; Genova Diagnostics; Health Associates Medical Group; Metabolic Solutions, Inc.; Pivotal Diagnostics; SIBO Diagnostics; SIBOTest; and Vibrant Wellness are among the leading companies in the North America small intestinal bacterial overgrowth (SIBO) diagnostics market. The companies are focused on adopting organic growth strategies such as product launches and expansions to sustain their position in the dynamic market. For instance, in 2018, Vibrant Wellness has launched IBSSure diagnostic platform for SIBO detection. Vibrant IBSSure is a tool to determine IgG antibodies to antigens – Vinculin and Cytolethal Distending Toxin B (CdtB) tested using a chemiluminescent technology delivering high sensitivity and specificity of detection.